JSP191 Antibody Targeting Conditioning in SCID Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions
SCID
Interventions
BIOLOGICAL

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Procedure: single intravenous infusion of JSP191 antibody

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

30322

Children's Healthcare of Atlanta, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55455

University of Minnesota, Minneapolis

90095

UCLA Mattel Children's Hospital, Los Angeles

94158

UCSF Benioff's Children's Hospital, San Francisco

94304

Lucile Packard Children's Hospital, Palo Alto

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY